Medical Gas Safety Act

H.R. 2227, the Medical Gas Safety Act; medical use of nitrous oxide and other anesthesia gasses. Reimbursement policies for anesthesia and respiratory therapy. Reauthorization of the Prescription Drug User Fee Act. S. 3187, The Food and Drug Administration Safety and Innovation Act, medical gas provisions.

Client expense: $120,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.2227 - Medical Gas Safety Act; H.R.971 - Critical Assessment and Improvement Act of 2011; H.R.5651 - Food and Drug Administration Reform Act of 2012; S.3187 - Food and Drug Administration Safety and Innovation; and The Patient Protection and Afforable Care Act

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1483, Drug Safety Enhancement Act of 2011: Provisions related to supply chain issues H.R. 2227, Medical Gas Safety Act: Provisions regarding the regulation of medical gases H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages H.R. 2674, 340B Program Improvement Act: Provisions related to 340B H.R. 3839, Drug Shortage Prevention Act of 2012: Provisions related to prescription drug shortages H.R. 4095, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases H.R. 4223, Safe Doses Act: Provisions related to supply chain security H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003 H.R. 4332, Generic Drug Application Review Fairness Act of 2012: Provisions related to FDA review and exclusivity H.R. 5651, Food and Drug Administration Reform Act of 2012: Provisions related to user fee reauthorization and FDA reform S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 810, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing S. 1002, Safe Doses Act: Provisions related to supply chain security S. 1584, Drug Safety and Accountability Act of 2011: Provisions related to supply chain issues S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B S. 2002, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform Comparative effectiveness policy issues Health care reform implementation issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues

H.R. 1483, Drug Safety Enhancement Act of 2011: Provisions related to supply chain issues H.R. 2227, Medical Gas Safety Act: Provisions regarding the regulation of medical gases H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages H.R. 2674, 340B Program Improvement Act: Provisions related to 340B H.R. 3204, Guidance Accountability and Transparency Act: Provisions to set forth interpretation policy of FDA guidance H.R. 3214, Food and Drug Administration Mission Reform Act of 2011: Provisions to revise the mission of the Food and Drug Administration H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3839, Drug Shortage Prevention Act of 2012: Provisions related to prescription drug shortages H.R. 4095, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases H.R. 4223, Safe Doses Act: Provisions related to supply chain security H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003 H.R. 4332, Generic Drug Application Review Fairness Act of 2012: Provisions related to FDA review and exclusivity H.R. 5651, Food and Drug Administration Reform Act of 2012: Provisions related to user fee reauthorization and FDA reform S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 1002, Safe Doses Act: Provisions related to supply chain security S. 1584, Drug Safety and Accountability Act of 2011: Provisions related to supply chain issues S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 2002, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform Comparative effectiveness policy issues Health care reform implementation issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues

HR 2227, Medical Gas Safety Act; S 3187, HR 5651, Food and Drug Administration Safety and Innovation Act (FDASIA), New Drug Application process and creation of a targeted regulatory scheme for medical gases.

Client expense: $160,000 · Firm income: Not reported

Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE

H.R. 2227, the Medical Gas Safety Act; medical use of nitrous oxide and other anesthesia gasses. Reimbursement policies for anesthesia and respiratory therapy. Reauthorization of the Prescription Drug User Fee Act. S. 3187, The Food and Drug Administration Safety and Innovation Act, medical gas provisions.

Client expense: $130,000 · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE

S.1387, The Food and Drug Admin. Safety and Innovation Act, Medical Gas Provisions H.R.2227, The Medical Gas Safety Act, all provisions

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.2227 Medical Gas Safety Act - to provide effective regulation of medical gases;

Client expense: $110,000 · Firm income: Not reported

Government targets: SENATE

FDA regulation of medical gas; H.R. 2227, Medical Gas Safety Act; S. 3187, the Food and Drug Administration Safety and Innovation Act.

Client expense: Not reported · Firm income: $120,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Regulation of medical gas product manufacturing; Medical Gas Safety Act (H.R. 2227); S.3187, the Food and Drug Administration Safety and Innovation Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2227, the Medical Gas Act; medical use of nitrous oxide and other anesthesia gasses. Reimbursement policies for anesthesia and respiratory therapy. Reauthorization of the Prescription Drug User Fee Act.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2227, Medical Gas Safety Act, National Drug Application process and creation of a targeted regulatory scheme for medical gases.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1483, Drug Safety Enhancement Act of 2011: Provisions related to supply chain issues H.R. 2227, Medical Gas Safety Act: Provisions regarding the regulation of medical gases H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages H.R. 2674, 340B Program Improvement Act: Provisions related to 340B H.R. 3204, Guidance Accountability and Transparency Act: Provisions to set forth interpretation policy of FDA guidance H.R. 3214, Food and Drug Administration Mission Reform Act of 2011: Provisions to revise the mission of the Food and Drug Administration H.R. 3839, Drug Shortage Prevention Act of 2012: Provisions related to prescription drug shortages H.R. 4095, Online Pharmacy Safety Act: Provisions to improve the safety of Internet pharmacies H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: Provisions to strengthen the FDAs ability to seek advice from external experts regarding rare diseases H.R. 4223, Safe Doses Act: Provisions related to supply chain security H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003 S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 1002, Safe Doses Act: Provisions related to supply chain security S. 1584, Drug Safety and Accountability Act of 2011: Provisions related to supply chain issues S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B S.2002, Online Pharmacy Safety Act: Provisions to improve the safety of Internet pharmacies S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters S.2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: Provisions to strengthen the FDAs ability to seek advice from external experts regarding rare diseases. Prescription Drug User Fee Act (PDUFA) reauthorization and related issues Comparative effectiveness policy issues Health care reform implementation issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues

Reauthorization of the Prescription Drug User Fee Act H.R.2227, The Medical Gas Safety Act, all provisions

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR2227 Medical Gas Safety Act HR971 Critical Care Assessment and Improvement Act of 2011 FDA Legislation including Prescription Drug and Medical Device User Fees

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Regulation of medical gas product manufacturing; Medical Gas Safety Act (H.R. 2227); Prescription Drug User Fee Act reauthorization.

Client expense: Not reported · Firm income: $40,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

FDA regualtion of medical gas; H.R. 2227, Medical Gas Safety Act.

Client expense: Not reported · Firm income: $120,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.2227 Medical Gas Safety Act - to provide effective regulation of medical gases;

Client expense: $40,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), SENATE

Reauthorization of the Prescription Drug User Fee Act H.R.2227, The Medical Gas Safety Act, all provisions

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2227, the Medical Gas Act; medical use of nitrous oxide and other anesthesia gasses. Reimbursement policies for anesthesia and respiratory therapy.

Client expense: $100,000 · Firm income: Not reported

Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE

Regulation of medical gas product manufacturing; Medical Gas Safety Act (H.R. 2227)

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation related to the Food and Drug Administration H.R.2227, the Medical Gas Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for H.R.2227 Medical Gas Safety Act - to provide effective regulation of medical gases;

Client expense: $40,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

HR 2227, Medical Gas Safety Act, requiring streamlined National Drug Application process and creation of a targeted regulatory scheme for medical gases.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR2227 Medical Gas Safety Act HR 971 Critical Care Assessment and Improvement Act of 2011 FDA Legislation including Prescription Drug and Medical Device User Fees

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation related to the Food and Drug Administration HR2227, the Medical Gas Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2227, Medical Gas Safety Act, requiring streamlined NDA process and creation of a targeted regulatory scheme for medical gases.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2227, the Medical Gas Act; medical use of nitrous oxide and other anesthesia gassses. Reimbursement policies for anesthesia and respiratory therapy.

Client expense: $100,000 · Firm income: Not reported

Government targets: Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

Legislation related to the Food and Drug Administration HR2227, the Medical Gas Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulation of medical gas product manufacturing; Medical Gas Safety Act (H.R. 2227)

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.2227 Medical Gas Safety Act - to provide effective regulation of medical gases

Client expense: $40,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

HR 971 Critical Care Assessment and Improvement Act of 2011 HR 2227 Medical Gas Safety Act FDA Legislation including Prescription Drug and Medical Device User Fees Drug Shortage Legislation

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Advise on standards-setting, verification, overseas programs, and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. - H.R. 1483, "Drug Safety Enhancement Act of 2011", regarding Section 102 on drug supply quality and safety. - H.R. 2227, "Medical Gas Safety Act", regarding Section 3, Regulation of Medical Gases. - H. 2112, "Agriculture Appropriations Bill, FY 2012", regarding support for FDA funding.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), SENATE

HR 2227, Medical Gas Act , Regulatory treatment of Nitrous oxide and other anesthesia gases. Reimbursement policies for anesthesia and respiratory therapy.

Client expense: $70,000 · Firm income: Not reported

Government targets: Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

S 1000 Energy Savings and Industrial Competitiveness Act of 2011; HR 2227, Medical Gas Safety Act.

Client expense: $200,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE